New particle can track chemo

Tracking the path of chemotherapy drugs in real time and at a cellular level could revolutionize cancer care and help doctors sort out why two patients might respond differently to the same treatment. Researchers at The Ohio State University have found a way to light up a common cancer drug so they can see where the chemo goes and how long it takes to get there.

They've devised an organic technique for creating this scientific guiding star and in doing so have opened up a new frontier in their field. Previous efforts have been limited by dyes that faded quickly and by toxic elements, particularly metals.

A study published this week in the journal Nature Nanotechnology highlighted two novel accomplishments. First, the researchers created a luminescent molecule, called a peptide and made up of two amino acids. Then they hitched that light to the cancer medication so that it revealed the chemo's arrival within cells.

"This is very important for personalized medicine. We really want to see what's going on when we give chemo drugs and this work paves the way for the exciting endeavor," said Dr. Mingjun Zhang, the biomedical engineering professor who led the study.

Biomedical engineers strive to find techniques that behave naturally within the body and leave without doing harm. This research holds promise for doing just that because the peptide is one that should easily coexist with human cells and leave as harmlessly as it entered.

"You can combine your drug with this luminescent vehicle," Zhang said of the tiny fluorescent particle devised in his lab. "Composed of natural amino acids, the nanoparticle is inherently biocompatible. Our biological machines can easily take care of it."

This work was done in petri dishes in Zhang's lab and work in animals is currently underway.

In the body or tissue of an animal or person, scientists would watch the fluorescent signal with an optical detection system, he said.

Zhang and his colleagues sandwiched their peptide to a common chemotherapy drug so that its light was hidden until the two elements peeled apart upon entering the cells.

Zhang was particularly delighted to see that the blue peptide, which can be seen under ultraviolet light, maintained its luminescence for extended periods of time. Previous work to track drugs using organic dyes has been hampered by their tendency to fade with time.

"You can label it and you can attach it to a drug and see where the drug goes and when it is released," Zhang said.

And it could be that the biomedical advance can give patients and their doctors information on how well and how quickly a medication is working for them.

"Maybe for some people a drug is taking effect in a few minutes and for somebody else it's hours and for somebody else it never takes effect," Zhang said.

The research team used doxorubicin, a widely used chemotherapy drug, for their lab work, but the discovery could apply to different types of treatments.

Better understanding of the complex interplay of cells and drugs is critical to development of treatments that are finely tuned for individual patients.

The Ohio State work builds on research that earned a trio of scientists the 2008 Nobel Prize in Chemistry. Their work on green fluorescent protein found in jelly fish led to the discovery that scientists could illuminate cellular-level activity that had previously been cloaked in mystery.

Zhang's work was supported by the National Science Foundation.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]